Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Public ClinicalTrials.gov record NCT05772169. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.
Study identification
- NCT ID
- NCT05772169
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 1,113 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2023 (Actual)
- Primary completion
- Nov 19, 2024 (Actual)
- Completion
- Dec 18, 2024 (Actual)
- Last update posted
- Jan 20, 2025
2023 – 2024
United States locations
- U.S. sites
- 36
- U.S. states
- 15
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 407 | Escondido | California | 92025 | — |
| Site 379 | Gardena | California | 90247 | — |
| Site 378 | Huntington Park | California | 90255 | — |
| Site 406 | La Jolla | California | 92037 | — |
| Site 373 | Los Angeles | California | 90057 | — |
| Site 387 | Tarzana | California | 91356 | — |
| Site 375 | Torrance | California | 90502 | — |
| Site 444 | Edgewater | Florida | 32132 | — |
| Site 015 | Fort Lauderdale | Florida | 33312 | — |
| Site 009 | Atlanta | Georgia | 30303 | — |
| Site 097 | Atlanta | Georgia | 30318 | — |
| Site 046 | Covington | Kentucky | 41011 | — |
| Site 061 | Metairie | Louisiana | 70006 | — |
| Site 377 | New Orleans | Louisiana | 70112 | — |
| Site 205 | New Orleans | Louisiana | 70121 | — |
| Site 410 | Baltimore | Maryland | 21239 | — |
| Site 394 | Hyattsville | Maryland | 20782 | — |
| Site 067 | Boston | Massachusetts | 02115 | — |
| Site 074 | Ann Arbor | Michigan | 48109 | — |
| Site 371 | Las Vegas | Nevada | 89128 | — |
| Site 070 | Albany | New York | 12208 | — |
| Site 411 | Smithtown | New York | 11787 | — |
| Site 181 | Chapel Hill | North Carolina | 27514 | — |
| Site 059 | Wilmington | North Carolina | 28401 | — |
| Site 436 | Cincinnati | Ohio | 45219 | — |
| Site 042 | Cleveland | Ohio | 44195 | — |
| Site 077 | Columbus | Ohio | 43210 | — |
| Site 195 | Columbus | Ohio | 43215 | — |
| Site 435 | Grants Pass | Oregon | 97527 | — |
| Site 049 | Portland | Oregon | 97239 | — |
| Site 456 | Cedar Park | Texas | 78613 | — |
| Site 370 | Dallas | Texas | 75230 | — |
| Site 408 | Lufkin | Texas | 75904 | — |
| Site 054 | San Antonio | Texas | 78207 | — |
| Site 369 | San Antonio | Texas | 78229 | — |
| Site 405 | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05772169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2025 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05772169 live on ClinicalTrials.gov.